Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)

NCT05823987 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Cancer

Interventions

DRUG: H101
DRUG: Tislelizumab
DRUG: Lenvatinib

Sponsor

Fudan University